Not Signed In - ADVENTRX Initiates CoFactor Phase II Clinical Trial In Refractory Breast Cancer
Sat, 30 Dec 2006 08:00 AM EST
... ADVENTRX Pharmaceuticals, Inc. (Amex: ANX) today announced the initiation of a Phase II clinical trial using CoFactor(R) in the treatment of refractory metastatic breast cancer. CoFactor (ANX-510) is a folate-based biomodulator drug designed to enhance the activity and reduce associated toxicity of the widely used cancer chemotherapeutic agent 5-fluorouracil (5-FU). [click link for full article] ...
Related Topics
- Clinical Trials
- Breast Cancer
- Pancreatic Cancer
- Bevacizumab Injection
- Trastuzumab
- Metastatic Cancer
- Breast Lumps & Other Breast Conditions
- Tarceva
- Cancers
- Breast Examination
- Ovarian Cancer
- Brain Cancer
- Epidemiology
- Breast Cancer, Male
- Male Breast Cancer
- Cancer--Living with Cancer
- Breast Reconstruction
- Breast Feeding
- Breast Implants
- Epidemiology & Prevention of Vaccine-Preventable Diseases
email this page
print this page
bookmark this page
feedback on this page
